Results 241 to 250 of about 17,756 (301)
Some of the next articles are maybe not open access.
Delayed Neutropenia with Ticlopidine
Annals of Pharmacotherapy, 1994OBJECTIVE: To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug. CASE SUMMARY: A 68-year-old woman was placed on ticlopidine after a transient ischemic attack. Ten days later the drug was discontinued because the patient developed a rash.
Lori A. Hansen, Debra K Farver
openaire +3 more sources
Thienopyridine (Ticlopidin, Clopidogrel) [PDF]
Hämostaseologie, 1998 ZusammenfassungThienopyridine (Ticlopidin und Clopidogrel) hemmen spezifisch die ADP-medi- ierten Mechanismen der Thrombozytenaktivierung. Der genaue molekulare Wirkmechanismus der Thrombozytenfunktionshemmung durch Thienopyridine ist nicht bekannt.
A.-A. Weber, K. Schrör
openaire +1 more source
Ticlopidine-induced thrombocytopenia
The Netherlands Journal of Medicine, 1999A case is presented of a 58-year-old woman developing profound thrombocytopenia within one week after starting treatment with ticlopidine. Ticlopidine was prescribed following coronary artery stenting. The patient recovered rapidly after discontinuation of the drug, suggesting a possible relationship between ticlopidine and thrombocytopenia ...
A. Loualidi +2 more
openaire +3 more sources
New England Journal of Medicine, 1989
We report the results of the Ticlopidine Aspirin Stroke Study, a blinded trial at 56 North American centers that compared the effects of ticlopidine hydrochloride (500 mg daily) with those of aspirin (1300 mg daily) on the risk of stroke or death.
W. Hass +6 more
semanticscholar +1 more source
We report the results of the Ticlopidine Aspirin Stroke Study, a blinded trial at 56 North American centers that compared the effects of ticlopidine hydrochloride (500 mg daily) with those of aspirin (1300 mg daily) on the risk of stroke or death.
W. Hass +6 more
semanticscholar +1 more source
Ticlopidine-theophylline interaction
Clinical Pharmacology and Therapeutics, 1987Ticlopidine, a new antithrombotic agent, and theophylline, a widely used bronchodilator drug, are both almost completely metabolized in the liver. To evaluate an interaction between these two drugs, we studied theophylline pharmacokinetics before, after 10 days of ticlopidine administration, and 1 month later in 10 healthy volunteers. We found a highly
Roberto Parravicini +5 more
openaire +3 more sources
, 2015
In the present study, the electrochemical behavior of ticlopidine was investigated by cyclic voltammetry, square-wave voltammetry and differential pulse voltammetry using a cathodically pretreated boron-doped diamond electrode.
Jéssica Scremin +2 more
semanticscholar +1 more source
In the present study, the electrochemical behavior of ticlopidine was investigated by cyclic voltammetry, square-wave voltammetry and differential pulse voltammetry using a cathodically pretreated boron-doped diamond electrode.
Jéssica Scremin +2 more
semanticscholar +1 more source
The mechanisms of action of ticlopidine
Thrombosis Research, 1983anti-platelet drug which was discovered in the laboratories of Parcor-Sanofi, Toulouse, France. This drug whose properties have been recently reviewed (1) has the potential as a clinically useful antithrombotic agent. It inhibits platelet aggregation induced by ADP and other aggregating agents (2).
openaire +3 more sources
Ticlopidine and Antiplatelet Therapy
Annals of Pharmacotherapy, 1993OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and toxicity of ticlopidine. Comparisons with other antiplatelet agents are presented, with an emphasis on efficacy, and a recommendation is provided regarding ticlopidine's place in therapy. DATA SOURCES: A MEDLINE literature retrieval of English-language journal articles from
Patricia Flores-Runk, Ralph H. Raasch
openaire +3 more sources
Drug Metabolism and Disposition, 2000
Ticlopidine is associated with a relatively high incidence of agranulocytosis and aplastic anemia. We have shown that other drugs associated with agranulocytosis are metabolized to reactive metabolites by activated human neutrophils or by HOCl, which is the major oxidant produced by activated neutrophils.
Z C, Liu, J P, Uetrecht
openaire +2 more sources
Ticlopidine is associated with a relatively high incidence of agranulocytosis and aplastic anemia. We have shown that other drugs associated with agranulocytosis are metabolized to reactive metabolites by activated human neutrophils or by HOCl, which is the major oxidant produced by activated neutrophils.
Z C, Liu, J P, Uetrecht
openaire +2 more sources
Journal of Neuroscience Nursing, 1992
Ticlopidine, a new prototype antiplatelet agent, offers a significant alternative in the primary and secondary prevention of atherothrombotic stroke. While 2 multicenter trials demonstrated benefits of ticlopidine, this drug is not without risks and limitations and more studies are indicated.
openaire +2 more sources
Ticlopidine, a new prototype antiplatelet agent, offers a significant alternative in the primary and secondary prevention of atherothrombotic stroke. While 2 multicenter trials demonstrated benefits of ticlopidine, this drug is not without risks and limitations and more studies are indicated.
openaire +2 more sources